Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
propranolol hydrochloride
- Development stage
- Approved
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Propranolol hydrochloride is a synthetic beta-adrenergic receptor blocking agent. It's a nonselective beta-blocker that works by blocking the effects of catecholamines on beta receptors, slowing heart rate and reducing blood pressure. It's used to treat hypertension, angina, atrial fibrillation, tremors, migraine prevention, and other cardiovascular conditions. It can also be used for infantile hemangioma treatment.
- Brand names
- InderalInderal LAInderal XLInnoPran XLHemangeol
- Other names
- propranolol
02
Targets
ADRB1 (β1)ADRB2 (β2)ADRB3 (β3)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR1B (5-Hydroxytryptamine Receptor 1B)
Beyond the preview
Go deeper on propranolol hydrochloride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on propranolol hydrochloride.